By Fineline Cube 
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a strategic cooperation agreement with Megarobo Technology, a leading provider of autonomous agents in robotics applications in China. The partnership aims to advance the digital and intelligent transformation of fully human antibody research and development (R&D) and production.
Collaboration Details
The strategic cooperation centers on leveraging the strengths of both parties to jointly develop an intelligent upgrading system. This system will cover antibody discovery, preparation, and screening. Megarobo’s Labillion Data Intelligence System and LibraX Intelligent Quality Control Platform will be integrated with Biocytogen’s Project Integrum to enhance efficiency and accuracy in antibody R&D and production.-Fineline Info & Tech